Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease
This economic evaluation examines the use, price, spending, and potential spending for roflumilast and apremilast from 2014 through 2024.
Authors
- Nikhita Perry (ORCID: https://orcid.org/0009-0000-1959-9090)
- John S. Barbieri (ORCID: https://orcid.org/0000-0002-5467-4102)
- Benjamin N. Rome (ORCID: https://orcid.org/0000-0001-5776-3293)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1001/jamadermatol.2025.3289
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00